COLL

Insider trade Sale by Freund John Gordon

12d ago

News Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD

14d ago

Insider trade Sale by Freund John Gordon

14d ago

Insider trade Sale by Lurker Nancy

17d ago

Insider trade Sale by Garen G Bohlin

19d ago

SEC filing COLL Acquires AZSTARYS for $650M, Raises 2026 Guidance to $865-895M Revenue, $475-500M Adjusted EBITDA

21d ago

News Collegium outlines $805M-$825M 2026 product revenue outlook while planning to close $650M AZSTARYS deal in Q2

25d ago

News Collegium Pharmaceutical Non-GAAP EPS of $1.76 beats by $0.24, revenue of $193.5M beats by $9.04M

26d ago

SEC filing COLL Reports $193.5M Rev, $38.9M JORNAY PM Rev Up 36%, $154.6M Pain Rev, $421.8M Cash, Acquires AZSTARYS for $650M Cash + $135M Milestones

26d ago

Insider trade Sale by David Dieter (EVP & General Counsel)

73d ago

Insider trade Sale by Scott Dreyer (EVP & Chief Commercial Officer)

88d ago

News Collegium targets 31% Jornay revenue growth for 2026 while advancing pain portfolio durability

95d ago

Scanner Unusual volume (3.1x average)

125d ago

News Trump admin rolls back $2B in mental health, addiction grant cuts—report

138d ago

News Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025

139d ago

News Collegium Pharmaceutical issues 2026 revenue guidance in line with estimates

145d ago